Has Charles Cummings, MD received payments from drug or device companies?

Yes. Drug and device makers reported $241,483 in general payments to Charles Cummings, MD across 956 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Charles Cummings, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Charles Cummings, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Charles Cummings, MD

Cardiovascular Disease · Baltimore, MDNPI 1881697233

Payments from drug & device makers

$241,483in general payments, 2019–2025

Across 956 payments — averaging $252.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Janssen Research & Development, LLC$127K
E.r. Squibb & Sons, L.L.C.$36K
Pfizer$19K
Novartis$18K
Sanofi-aventis U.S. LLC$11K
Regeneron Healthcare Solutions, Inc.$10K
plus $20K from 48 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Janssen Research & Development, LLC	10	$127,127
E.r. Squibb & Sons, L.L.C.	150	$35,717
Pfizer	65	$19,081
Novartis	145	$18,217
Sanofi-aventis U.S. LLC	15	$11,278
Regeneron Healthcare Solutions, Inc.	24	$10,348
AstraZeneca	45	$3,953
Boston Scientific	49	$3,391
Abbott	90	$3,338
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	40	$933
Medtronic(2 entities)	22	$770
Johnson & Johnson	47	$767
Novo Nordisk	34	$724
Boehringer Ingelheim	22	$571
Edwards Lifesciences	5	$556
Amgen	25	$487
Abiomed	15	$416
Merck	22	$366
Esperion Therapeutics, Inc.	9	$325
Biotronik Inc.	18	$281
Chiesi USA, Inc.	19	$255
Kestra Medical Technology Services, Inc.	5	$254
Heartflow, Inc.	5	$235
Irhythm Technologies, Inc.	6	$233
Atricure, Inc.	3	$228
Inari Medical, Inc.	2	$189
Shockwave Medical, Inc	2	$148
Cvrx, Inc.	1	$138
Amarin Pharma, Inc.	7	$123
Terumo Medical Corporation	6	$101
Philips North America LLC	4	$95
Bardy Diagnostics, Inc.	4	$85
Scpharmaceuticals Inc.	4	$79
Alnylam Pharmaceuticals Inc.	3	$73
Lundbeck LLC	4	$57
Kiniksa Pharmaceuticals International, PLC	3	$56
Preventice Services, LLC	1	$47
Kowa Pharmaceuticals America, Inc.	3	$46
Bayer	2	$39
Actelion Pharmaceuticals US, Inc.	2	$39
Bridgebio Pharma, Inc.	2	$39
Teleflex LLC	2	$38
GSK	2	$36
Kiniksa Pharmaceuticals, Ltd.	2	$29
Getinge USA Sales, LLC	1	$29
Baxter Healthcare	1	$21
Cook Medical LLC	1	$19
Medicomp Inc	1	$18
GE HealthCare	1	$17
Gilead	1	$16
Inspire Medical Systems, Inc.	1	$14
Itamar Medical Inc	1	$14
Cardiva Medical, Inc.	1	$14
Arbor Pharmaceuticals, Inc.	1	$13

How this compares

$241,483 in reported general payments places this provider in the 90th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland →

Medicare billing

Part B allowed, 2024

$433,960

Medicare patients

2,645

Services billed

7,523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Baltimore

Christopher DefilippiBaltimore$9.2M
Thorsten LeuckerBaltimore$7.1M
Joao LimaBaltimore$5.6M
Jeffrey ColeBaltimore$4.8M
Carlos InceBaltimore$3M
Paul GurbelBaltimore$2.6M
Navin KapurBaltimore$1.8M
Robert WeissBaltimore$1.4M
Stephen GottliebBaltimore$1.4M
Jesse DoranBaltimore$1.1M

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →